#China #Shanghai #Harbour BioMed #Michael Patten #strategy officer

Harbour BioMed Welcomes Michael D. Patten as Chief Strategy Officer

On March 10, 2025, Harbour BioMed, a leading global biopharmaceutical company specializing in innovative antibody therapeutics, announced the appointment of Michael D. Patten as its Chief Strategy Officer. Patten, who will operate mainly from the United States, is set to report directly to Dr. Jingsong Wang, the company's founder and CEO.

In this new role, Patten will shape and oversee Harbour BioMed's corporate growth and development strategies. His significant experience will also play a crucial role in managing the company's global alliance network, especially targeting high-potential markets outside China, which will enhance Harbour BioMed's brand visibility and market presence.

Michael D. Patten brings a wealth of experience from his previous roles at Bristol Myers Squibb, where he led multiple key initiatives. His last position at the company was as Head of Equity Venture Capital, where he spearheaded numerous significant equity investments and commitments. This role, along with his positions in Business Development and Alliance Leadership, has equipped him with the necessary skills to navigate the complexities of the biopharmaceutical landscape effectively.

Dr. Jingsong Wang expressed excitement regarding Patten's appointment, citing that Michael's extensive expertise aligns well with the company's mission to develop and commercialize innovative biotherapeutics. “With his leadership, we anticipate a substantial expansion of our global reach,” Wang commented.

In joining Harbour BioMed, Patten conveyed enthusiasm for the company's vision, particularly its commitment to addressing unmet medical needs. He stated, “The potential here is tremendous. I look forward to driving initiatives that will foster growth and deliver groundbreaking therapies to patients worldwide.”

Patten holds a Bachelor of Science degree with Joint Honors in Pharmacology and Business Studies from the University of Edinburgh, a Master of Science in Pharmaceutical Medicine from the University of Surrey, and an MBA from the University of Maastricht. His strong academic background complements his professional experience, making him well suited for the challenges ahead.

About Harbour BioMed
Harbour BioMed (HKEX: 02142) is focused on the discovery, development, and commercialization of innovative antibody therapeutics aimed at treating challenges in immunology and oncology. The company leverages its proprietary technology, including the Harbour Mice® platform which allows for the generation of fully human monoclonal antibodies, and the unique HBICE® bispecific antibody technology that enhances therapeutic efficacy. With a commitment to building a robust and differentiated pipeline through internal capabilities and strategic collaborations, Harbour BioMed strives to deliver effective treatment options for patients globally.

For further information, please visit www.harbourbiomed.com.